415. Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
作者: David B Meya.;Fiona V Cresswell.;Biyue Dai.;Nicole Engen.;Kogieleum Naidoo.;Ahmad Rizal Ganiem.;Darma Imran.;Mable Kabahubya.;Richard J Lessells.;Vycke Yunivita.;Riwanti Estiasari.;Lillian Tugume.;Bongeka Hlabisa.;Media Yuni Kurniawati.;Noveline Sagita.;Enock Kagimu.;Kartika Maharani.;Jane Gakuru.;Maula N Gaharu.;Timothy Mugabi.;Sarah Kimuda.;Suzan Namombwe.;Lindsey Te Brake.;Rob Aarnoutse.;Elin M Svensson.;Ananta S Bangdiwala.;Sylvia Namanda.;Nathan C Bahr.;Abdu K Musubire.;Mahomed Yunus Suleman Moosa.;Raph L Hamers.;Suzaan Marais.;David R Boulware.;Reinout van Crevel.;Rovina Ruslami.; .
来源: N Engl J Med. 2025年393卷24期2434-2446页
Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervous system penetration. Whether high-dose rifampin could improve survival outcomes is unknown.
416. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
作者: Stephen J Nicholls.;Imre Pavo.;Deepak L Bhatt.;John B Buse.;Stefano Del Prato.;Steven E Kahn.;A Michael Lincoff.;Darren K McGuire.;Debra Miller.;Michael A Nauck.;Hiroshi Nishiyama.;Steven E Nissen.;Naveed Sattar.;Govinda Weerakkody.;Russell J Wiese.;Bernard Zinman.;Sophia Zoungas.;Jan Basile.;Melanie J Davies.;Francesco Giorgino.;Monika Kellerer.;Linong Ji.;Tamas Varkonyi.;Venu Menon.;Jonathan C Broder.;Alan Herschtal.;David D'Alessio.; .
来源: N Engl J Med. 2025年393卷24期2409-2420页
Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain.
|